(For ED pills and Addyi screening, doctors are required to chat with the patient before making a diagnosis.) Once patients get their prescriptions, they also get automated follow-up check-ins from Hims or Hers telling patients to share how things are going with the medication or treatment
Any suspected side effects from retatrutide or other unlicensed products should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk
"Studies with longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment," write the researchers
Although NSW is currently as a Group 2 A carcinogen, this assessment is primarily based on mechanistic evidence and limited epidemiological data 1
These are mechanisms and biomarkers, not outcomes
Its best to consult with your healthcare provider to determine the most appropriate treatment plan for you.